Both findings are consistent with the results obtained in our series, where the composite endpoint incidence was higher in the non-SCB group (22.6%) compared with the SCB-treated group (11.9%); however, this difference did not reach statistical significance.
← all excerpts
The Clinical Safety and Efficacy of Sodium Channel Blocker Therapy for Rhythm Control in Atrial Fibrillation: Insights from the REGUEIFA Registry.
1
—
—